Cardiometabolic News and Research

RSS

Could a few days of annual extreme heat raise dementia risk?

Extreme outdoor heat is associated with higher dementia risk, especially in socially vulnerable areas, emphasizing the need for targeted community strategies.

27 Oct 2026

Millions get GLP-1 drugs through channels insurance records may miss

Researchers analyzed reports from 9,150 US adults and found that current or previous GLP-1/GIP use rose from 8.2% to 12% between March 2024 and October 2025, largely driven by weight-loss indications. They also estimated that approximately one-third of users obtained treatment through nontraditional channels that standard insurance claims may fail to capture.

26 Oct 2026

Taking a GLP-1 drug? Here's what the safety evidence really shows

A review on GLP-1 receptor agonists highlights risks like pancreatitis and thyroid cancer, emphasizing individual patient risk over general safety concerns.

26 Oct 2026

A study of 802 teens raises questions about school breakfast and blood sugar

A study of 802 U.S. adolescents found that school breakfast participation at least once weekly was associated with a 30% higher prevalence of prediabetes-range glucose markers, while school lunch participation showed no significant association. Higher intakes of vitamins E and B6 and fruit consumption among adolescents with obesity were associated with lower prediabetes prevalence, but none of the reported associations remained statistically significant after correction for multiple comparisons.

22 Oct 2026

Depression profile linked to disrupted sleep and poorer treatment responses

This study uncovers a circadian depression subtype, revealing links between sleep patterns, symptom severity, and antidepressant response in a large cohort.

22 Oct 2026

Beef can fit into healthy diets, but what about its environmental cost?

A narrative review published in Animal Frontiers highlights beef's contribution to high-quality protein and bioavailable micronutrients, while controlled trials generally found no adverse effects on selected cardiometabolic risk markers, although long-term disease outcomes remain uncertain. The authors argue that sustainable food policies should consider nutritional needs, environmental impacts, agricultural productivity, and rural livelihoods when evaluating beef's place in healthy diets.

21 Oct 2026

ScionxBio announces collaboration to develop long-acting xRNA therapeutics

ScionxBio (the "company", operating as a brand identity of Eleven Therapeutics Ltd. following a horizontal split) a privately held, preclinical-stage biotechnology company pioneering next-generation mRNA therapeutics, distinguished by their extended durability profile, today announced that it has entered into a worldwide strategic collaboration and licensing agreement with Sanofi to develop and commercialize extended exposure versions of certain Sanofi mRNA candidates by leveraging ScionxBio's proprietary TERA® platform.

From ScionxBio 21 Oct 2026

Premature menopause linked to higher heart disease risk and insulin levels

Premature menopause is associated with an increased risk of several long-term health problems due to estrogen deficiency.

20 Oct 2026

Blood pressure drug losartan boosts metabolism by stimulating brown fat

Losartan, a drug commonly prescribed for high blood pressure, boosts brown adipose tissue or "brown fat" activity and enhances its metabolism, according to a preclinical study by Weill Cornell Medicine, Rockefeller University and Memorial Sloan Kettering Cancer Center researchers.

19 Oct 2026

Could ultraprocessed foods affect your brain before you notice?

Ultraprocessed food intake correlates with increased body fat and vascular brain injury in middle-aged adults, though cognitive performance remains unaffected.

19 Oct 2026

AI study of 101,000 patients links brown fat to heart and mental health

In a retrospective analysis of PET-CT records from 101,243 patients, researchers found that detectable brown fat was associated with lower prevalence of cardiometabolic and psychiatric conditions, while greater activity, particularly in the axillary region, was linked to more favourable metabolic outcomes. Medication screening identified losartan, which increased brown fat thermogenic activity in laboratory experiments and energy expenditure in mice, although its effects on human brown fat remain unproven.

15 Oct 2026

Experts call for lifelong care after brain and spinal injuries

In a new paper published in The Lancet Neurology, "Reframing traumatic brain injury and spinal cord injury as chronic multisystem disorders: toward integrated, long-term care," international experts across institutions and disciplines propose a fundamental shift in how traumatic brain and spinal cord injuries in adults are understood and managed. Sandro Marini, MD, of the Mass General Brigham Neuroscience Institute, is a co-first author, and Saef Izzy, MD, also of the Neuroscience Institute, is one of the co-senior authors, and the primary corresponding author.

14 Oct 2026

Losing weight is one thing. Keeping your muscle is another, experts say

The International Society of Sports Nutrition (ISSN) position stand concludes that sustained calorie restriction drives weight loss, while adequate protein intake and resistance training help preserve lean mass. Reviewing intermittent fasting, ketogenic diets, and other dietary approaches, the authors emphasize individualized nutrition plans, body composition, and sustainable weight management rather than rapid weight loss alone.

14 Oct 2026

Common blood pressure drug boosts brown adipose tissue activity and metabolism

Scientists have discovered that the drug losartan, commonly prescribed for high blood pressure, boosts brown adipose tissue activity in mice, enhancing their metabolism.

14 Oct 2026

Diet drinks showed no clear weight-loss edge over water after two years

In a two-year randomized trial combining assisted weight management with an unassisted follow-up year, completers maintained average weight losses of 4.8 kg with diet drinks and 3.7 kg with water. Researchers found no significant difference between groups, but fewer than half of the 493 participants completed follow-up.

11 Oct 2026

Stopping GLP-1 drugs often brings weight back. A small trial suggests ways to slow it

In a randomized pilot trial of 39 adults, researchers found that participants receiving medically tailored meals or Noom regained about 3.6% of their body weight over four months after stopping GLP-1 therapy, compared with about 11% under usual care. These exploratory findings suggest structured support may slow early weight regain, but the small sample and short follow-up leave lasting benefits uncertain.

11 Oct 2026